Lumira Ventures
VC Fund
Toronto, Canada
Lumira Ventures is a VC fund in Toronto focused on Biotechnology and Health Care. With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meetingsignificant unmet needs and creating transformation impact in communities worldwide.Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.
- Total investments:
- 119
- Last investment:
- Lead investor:
- 30%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lumira Ventures invests in
Stages Lumira Ventures invests in
Countries Lumira Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.9M–$105M
- Series B
- $12M–$75M
Investment Focus
Industry
- Biotechnology 45 (38%)
- Health Care 32 (27%)
- Medical 22 (18%)
- Therapeutics 21 (18%)
- Medical Device 16 (13%)
Stage
- Series A 22 (18%)
- Series B 16 (13%)
- Funding Round 12 (10%)
- Series C 11 (9%)
- Series D 10 (8%)
Country
- United States 34 (29%)
- Canada 24 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Baye Galligan, M.A., HBA
Associate
|
Associate | Total investments: 0 | Find email | |
Benjamin Rovinski
Managing Director
|
Managing Director | Total investments: 10 | Find email | |
Brian J. Underdown, Ph.D.
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Daniel Hetu
Managing Director
|
Managing Director | Total investments: 11 | Find email | |
Lu Han
Director, Business Development Asia Pacific
|
Director, Business Development Asia Pacific | Total investments: 2 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cour Pharmaceuticals Development
|
Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | |
Contraline
|
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible. | $92.5M / Series B / Jun 02, 2026 | |
Nervonik
|
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M / Series B / Apr 27, 2026 | |
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M / Venture - Series Unknown / Mar 19, 2026 | |
Nocion Therapeutics
|
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | |
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | |
|
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M / Venture - Series Unknown / Sep 04, 2025 | |
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Private Equity / Aug 07, 2025 | |
Corvia Medical
|
Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts. | $55M / Jun 17, 2025 | |
Puzzle Medical Devices
|
Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $30.2M / Series A / Apr 08, 2025 | |
| See all 119 investments → | |||
Co-Investors
Fonds de solidarité FTQ
16 deals together
Amzak Health Investors
8 deals together
adMare Bio Innovations
7 deals together
Hatteras Venture Partners
7 deals together
RA Capital Management
7 deals together
Viva BioInnovator
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Lumira Ventures invest in?
Lumira Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 119 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Lumira Ventures's check size?
Lumira Ventures typically joins rounds of $2.9M–$105M at Series A and $12M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Lumira Ventures participates in.
How do I contact Lumira Ventures?
Public channels for Lumira Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lumira Ventures?
The team at Lumira Ventures includes Baye Galligan, M.A., HBA (Associate), Benjamin Rovinski (Managing Director) and Brian J. Underdown, Ph.D. (Venture Partner), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
